CIVCO Radiotherapy & Stratpharma AG Healthcare Announce Global Collaboration for Renewed & Revolutionary Patient Care

Monday, April 29, 2019

CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions and Stratpharma AG, a Swiss company that specializes in innovative topical medical products to improve post-procedure outcomes, have expanded their partnership to focus on wound care for radiation therapy patients.  This initiative aligns with the missions of both companies to focus on patient outcomes in the radiation therapy space.

CIVCO and its world-class global distribution network will be the global distributors of the StrataXRT® product, an innovative wound dressing for the treatment for radiation dermatitis. Acute radiation-induced skin reactions are an inevitable consequence of radiation therapy and occur in up to 95% of patients receiving treatment to the breast, groin or perineum.  StrataXRT is a self-drying gel wound dressing, developed to be used during and after radiation treatment.

"The StrataXRT product truly aligns with our mission of improving patient outcomes worldwide.  This innovative product and exciting collaboration allows us to expand our patient-centric focus, not only on patient comfort during treatment, but also on patient wellness during and after treatment," said Nat Geissel, president of CIVCO Radiotherapy.

"We are pleased to be working closely with CIVCO Radiotherapy and their synergies worldwide in this new approach to provide innovative solutions to radiation patients, improving overall outcomes," said Darren Kerr, Stratpharma AG CEO.